FDA's communication says the agency requested that manufacturers remove suicidal behavior and ideation warning language from the labels of certain GLP-1 receptor agonist medicines. 1
The FDA communication names Wegovy, Zepbound, and Saxenda. This update reports the agency's labeling request and does not provide an individualized interpretation of safety. 1
What this source can tell us. PeptideScanner is reporting the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.